Equities Analysts Set Expectations for VERA FY2027 Earnings

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Wedbush raised their FY2027 EPS estimates for shares of Vera Therapeutics in a note issued to investors on Monday, June 2nd. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($2.04) for the year, up from their previous forecast of ($3.14). Wedbush has a "Neutral" rating and a $26.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Wedbush also issued estimates for Vera Therapeutics' FY2028 earnings at $0.12 EPS and FY2029 earnings at $1.77 EPS.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period in the prior year, the business posted ($0.56) EPS.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright increased their price target on Vera Therapeutics from $75.00 to $85.00 and gave the company a "buy" rating in a research note on Monday. JPMorgan Chase & Co. decreased their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Scotiabank boosted their price target on shares of Vera Therapeutics from $55.00 to $65.00 and gave the stock a "sector outperform" rating in a research report on Monday. Guggenheim upped their price objective on shares of Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Finally, Cantor Fitzgerald decreased their price objective on shares of Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $65.00.

Vera Therapeutics Trading Down 4.3%

NASDAQ:VERA traded down $1.37 during trading hours on Thursday, hitting $30.63. 3,478,292 shares of the company were exchanged, compared to its average volume of 879,593. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -11.74 and a beta of 1.13. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.61. The company has a fifty day simple moving average of $22.26 and a 200 day simple moving average of $31.86. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of VERA. Barclays PLC lifted its position in shares of Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after purchasing an additional 41,394 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Vera Therapeutics during the 4th quarter valued at $2,948,000. Victory Capital Management Inc. raised its stake in shares of Vera Therapeutics by 515.0% during the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock valued at $9,949,000 after purchasing an additional 197,014 shares during the period. Teacher Retirement System of Texas lifted its holdings in shares of Vera Therapeutics by 44.2% in the fourth quarter. Teacher Retirement System of Texas now owns 12,860 shares of the company's stock worth $544,000 after buying an additional 3,942 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock valued at $124,737,000 after purchasing an additional 369,387 shares during the period. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.